Celecoxib Market

How big is the Celecoxib market in 2026?

USD 13.21 million in 2026 and USD 18.10 million by 2036 at a 3.2% CAGR.

The celecoxib industry value is predicted to rise from USD 12.80 million in 2025 to USD 18.10 million by 2036 at 3.2% CAGR as regulated active pharmaceutical ingredient buyers continue product maintenance across arthritis and pain-management formulations. Crystalline form is expected to account for 64.0% share in 2026, reflecting solid-form control required for oral dosage manufacturing. Finished-dosage manufacturers are anticipated to account for 61.0% share in 2026, reflecting product-file ownership and batch-release responsibility.

Metric	Value
2026 Market Size	USD 13.21 million
2036 Market Size	USD 18.10 million
Forecast CAGR	3.2% from 2026 to 2036
Leading Form	Crystalline
Crystalline Share in 2026	64.0%
Leading Purity Grade	99.5% or Higher
Finished-Dosage Manufacturers Share in 2026	61.0%
Leading CAGR Country	United States
United States CAGR	3.6% by 2036

Summary of the Celecoxib Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Celecoxib API demand is supported by regulated generic medicine production and supplier qualification requirements. Finished-dosage manufacturers continue placing repeat API orders for approved arthritis and pain-management formulations. Regulated buyers require suppliers capable of providing impurity data, regulatory documentation, and batch-release records. Direct supplier agreements are gaining preference as product owners seek audit access before commercial procurement.
Product and Segment View	Crystalline APIs, finished-dosage manufacturers, and high-purity grades lead the market. Crystalline form is expected to account for 64.0% of the 2026 market (by form), supported by consistent particle behavior and oral dosage performance. Finished-Dosage Manufacturers are anticipated to hold 61.0% of the 2026 market (by end user), reflecting product-file ownership and regulated batch-release obligations. 99.5% or higher purity grade is projected to secure 58.0% of the 2026 market (by purity), driven by stringent impurity requirements for regulated capsule production.
Geography and Growth Outlook	The United States and the United Kingdom are expected to remain key regulated markets. The United States is projected to grow at a 3.6% CAGR (2026–2036), supported by broad capsule-strength availability and continued generic demand. The United Kingdom is expected to expand at a 3.4% CAGR (2026–2036), driven by NHS tariff visibility and finished-dose supply continuity.
Competitive Landscape	Competition is driven by regulatory compliance, documentation quality, and manufacturing capability. Hikal and Aurore Life Sciences compete through API manufacturing expertise and strong regulatory documentation. Aarti Drugs, Axplora/Farmabios, Hetero Labs, Glochem Industries, Saurav Chemicals, and Shenzhen HwaGen Pharmaceutical compete through particle-form control and regional market access.
Analyst Perspective	Celecoxib API has become a quality-driven market where regulatory reliability outweighs product novelty. Buyers prioritize dependable batch release, regulatory documentation, and audit-ready manufacturing over price alone. Generic pricing pressure is reshaping supplier strategies rather than reducing demand for the molecule. Suppliers with strong DMF capabilities and consistent particle-size control are expected to secure long-term contracts more effectively than low-cost competitors. — Anurag Sharma, Principal Consultant, Healthcare, Future Market Insights

Regulated capsule programs keep celecoxib API commercially active across mature generic channels. FDA's May 2025 product-specific guidance listed celecoxib capsule strengths of 50 mg, 100 mg, 200 mg, and 400 mg and recommended one fasting in vivo bioequivalence study on the 400 mg strength.

Indian Pharmacopoeia Commission's June 2024 draft for Celecoxib Capsules specified content limits of 95.0% to 105.0% of stated celecoxib and usual strengths of 100 mg and 200 mg. Axplora's April 2024 product portfolio listed Celecoxib Form III in fine and micronized grades, supported by CEP and Canada DMF pathways. API suppliers gain value as product holders need controlled crystal behavior and regulator-ready files.

Which factors support expansion in the Celecoxib market?

Finished API supply and documentation-linked renewal programs support market value across regulated celecoxib products.

• API value rises as product holders maintain approved capsule lines across arthritis and pain applications.
• Crystalline API supports manufacturing consistency by helping formulators manage blending and dissolution behavior.
• High-purity material improves supplier qualification as impurity changes can trigger added stability work.
• Direct supply contracts protect buyer access to batch data and change-control communication.

Why is the Celecoxib market growing?

Arthritis and pain-care demand support repeat API ordering as approved capsule products stay active in regulated channels.

Celecoxib API demand benefits from recurring pain-management and anti-inflammatory use across adult patients. CDC's November 2024 data brief reported that 24.3% of United States adults had chronic pain and 8.5% had high-impact chronic pain in 2023, supporting continued demand for pain-care medicines. Finished-dose manufacturers need stable API input for established capsule lines across rheumatoid arthritis and acute pain. Suppliers able to provide stronger purity files and solid-form consistency gain better access to renewal programs.

How is the Celecoxib Market segmented?

Celecoxib Market is segmented by form, purity grade, application, sales channel, and buyer type.

• Crystalline is projected to account for 64.0% share in 2026, influenced by solid-form control required for oral capsule manufacturing.
• 99.5% or Higher purity grade is expected to hold 58.0% share in 2026, guided by impurity discipline across regulated product files.
• Osteoarthritis is anticipated to account for 50.0% share in 2026, supported by repeat oral pain-management formulations.
• Direct sales are projected to hold 52.0% share in 2026, shaped by audit access and change-control support.
• Finished-Dosage Manufacturers are expected to hold 61.0% share in 2026, driven by product-file ownership and batch-release obligations.

Why does crystalline form lead Celecoxib API demand?

• Crystalline is projected to account for 64.0% share in 2026, driven by solid-form control needed in capsule blending and release consistency.
• Powder remains useful for smaller batches and early formulation work. Commercial accounts place stronger value on repeatable crystal behavior.

Which purity grade leads the Celecoxib market?

• 99.5% or Higher purity grade is expected to hold 58.0% share in 2026, shaped by impurity limits and smoother regulatory review.
• 98.0% to 99.5% material supports development-linked orders, while regulated finished-dose suppliers usually favor cleaner API files.

Which application leads the Celecoxib market?

• Osteoarthritis is anticipated to account for 50.0% share in 2026, led by recurring oral pain-management use and established capsule production.
• Rheumatoid arthritis and acute pain add smaller demand pools, helping keep the molecule active across approved therapeutic uses and rheumatoid arthritis therapeutics.

Which sales channel leads the Celecoxib market?

• Direct sales are projected to hold 52.0% share in 2026, reflected by regulated buyers needing audit access and supplier accountability.
• Distributors and online API marketplaces support supplier discovery and early comparison before technical qualification begins.

Which buyer type leads the Celecoxib market?

• Finished-Dosage Manufacturers are expected to hold 61.0% share in 2026, guided by product-file control and release obligations linked to celecoxib capsules.
• Contract manufacturers and regulatory-file developers influence early sourcing. Final commercial supply depends on product-holder approval.

What are the drivers, restraints, and opportunities in the Celecoxib Market?

Generic pain-management demand and quality-led supplier qualification shape celecoxib API buying.

• Driver: Finished-dosage continuity supports repeat API orders for established osteoarthritis and acute pain products.
• Restraint: Generic price pressure can limit supplier margins even as product use continues across capsule programs.
• Opportunity: Suppliers offering particle-size control and regulator-ready files can defend accounts during supplier reviews.

Capsule Strength Breadth Supports Repeat API Demand

Celecoxib capsule supply remains active across regulated finished-dose channels. DailyMed material lists celecoxib as an oral capsule available in 50 mg, 100 mg, 200 mg, and 400 mg strengths. Multiple strengths keep formulation demand spread across chronic and short-course pain use. API suppliers providing stable release behavior and consistent particle-size records can retain recurring purchase programs.

Generic Price Discipline Raises Supplier Burden

Generic medicine competition keeps buyer negotiations tight for mature API suppliers. FDA's May 2026 Office of Generic Drugs page stated that generic drugs account for more than 90% of prescriptions filled in the United States. Product holders therefore have limited room to absorb API price increases during renewals. API sellers with weak response systems face slower qualification under active product-file maintenance.

DMF Visibility Creates Qualification Advantage

Regulatory master-file transparency creates room for suppliers that can support method transfer and quality review. FDA's April 2026 DMF inventory uses two acceptance cutoffs before a file appears in public records, receipt by March 31, 2026 and acknowledgement before April 22, 2026. Filing discipline gives buyers a faster way to screen API suppliers during source review. Documentation depth can reinforce commercial access across regulated API sourcing.

Which countries are prominently growing in the Celecoxib market?

United States 3.6% CAGR, United Kingdom 3.4% CAGR, France 3.1% CAGR, Germany 2.9% CAGR, Japan 2.7% CAGR, South Korea 2.4% CAGR, China 1.8% CAGR, and India 1.6% CAGR through 2036.

Country	CAGR
United States	3.6%
United Kingdom	3.4%
France	3.1%
Germany	2.9%
Japan	2.7%
South Korea	2.4%
China	1.8%
India	1.6%

Source: Future Market Insights, 2026.

How do country-level CAGRs compare in the Celecoxib Market?

United States leads country expansion while India records the most cautious pace among profiled markets.

United States is forecast to record 3.6% CAGR by 2036, driven by capsule-strength breadth and generic guidance activity.

• United Kingdom is expected to expand at 3.4% CAGR from 2026 to 2036, led by NHS tariff visibility and finished-dose continuity.
• France is projected to grow at 3.1% CAGR through 2036, supported by generic directory activity and EU product maintenance.
• Germany is estimated to rise at 2.9% CAGR by 2036, reflected by regulated continuity and dossier-linked supplier discipline.
• Japan is expected to advance at 2.7% CAGR over the forecast period, guided by pharmacopoeial activity and careful supplier review.
• South Korea is forecast to grow at 2.4% CAGR by 2036, backed by regulated generic access and import-document expectations.
• China is projected to post 1.8% CAGR by 2036, guided by domestic generic capacity and approval activity.
• India is expected to record 1.6% CAGR by 2036, driven by API manufacturing depth and export documentation.

How is the Celecoxib Market performing in the United States?

A 3.6% CAGR through 2036 reflects capsule-strength breadth and active generic guidance.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 2.34 million
Market Size in 2026 (Value)	USD 2.42 million
Market Forecast in 2036 (Value)	USD 3.45 million
CAGR (2026 to 2036)	3.6%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	Northeast and Midwest generic formulation corridors

United States Celecoxib Market Outlook

• United States celecoxib API demand is supported by generic capsule manufacturing and active regulatory maintenance. Product holders need stable API files to protect ANDA-linked supply and release schedules.
• Suppliers are expected to compete through DMF access and technical response speed. Finished-dose buyers will favor vendors that reduce validation work during product maintenance.

Key Growth Drivers

• Generic capsule programs need product-specific testing discipline, shown by FDA's May 2025 guidance recommending one fasting in vivo bioequivalence study on the 400 mg strength.
• Finished-dose scope stays spread across several capsule options, documented by DailyMed listing celecoxib capsules in 50 mg, 100 mg, 200 mg, and 400 mg strengths.
• ANDA holders need dependable API sources to avoid batch-release and file-maintenance delays.
• Direct API relationships support DMF letters and change-control communication.

Key Restraints

• Generic competition can compress API margins during renewal negotiations.
• Safety-language updates add document work for product holders and suppliers, reflected by FDA's November 2024 Celebrex approval letter requiring labeling content submission within 14 days.
• Supplier switching may require extra dissolution and formulation review before commercial purchase expands.

What makes United States unique

United States stands out through ANDA-linked sourcing and active product-specific guidance.

Key Companies

• Viatris (Mylan)
• Teva Pharmaceuticals USA
• Amneal Pharmaceuticals
• Lupin Pharmaceuticals
• Dr. Reddy's Laboratories Inc.
• Pfizer/Greenstone

Sales & Marketing Channels

• Direct API contracts with ANDA holders
• Distributor access for early supplier comparison
• DMF-linked technical qualification
• Quality-audit driven account development
• Formulation support through customer technical teams
• Online API discovery followed by direct qualification

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	99.5% or Higher · 98.0% to 99.5% · Below 98%
By Application	Osteoarthritis · Rheumatoid Arthritis · Acute Pain
By Sales Channel	Direct · Distributors · Online API Marketplaces
By Buyer Type	Finished-Dosage Manufacturers · API Distributors · Contract Manufacturers · Regulatory-File Developers · Generic Product Sponsors
Key Sub-Regions Covered, Formulation Corridors	Northeast · Midwest · New Jersey · Pennsylvania · North Carolina · California

Frequently Asked Questions

How fast is United States Celecoxib market growing?

United States demand is projected to rise at 3.6% CAGR from 2026 to 2036, backed by capsule-strength breadth and active generic guidance.

Who leads United States Celecoxib market?

Viatris (Mylan), Teva Pharmaceuticals USA, Amneal Pharmaceuticals, Lupin Pharmaceuticals, Dr. Reddy's Laboratories Inc., and Pfizer/Greenstone lead United States Celecoxib market through approved generic products and established distribution.

What is driving adoption in United States Celecoxib market?

ANDA-linked capsule production and product-specific testing expectations are moving United States buyers toward documented API suppliers.

What is the Celecoxib Market outlook in the United Kingdom?

A 3.4% CAGR through 2036 reflects NHS tariff visibility and finished-dose continuity.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 0.77 million
Market Size in 2026 (Value)	USD 0.80 million
Market Forecast in 2036 (Value)	USD 1.12 million
CAGR (2026 to 2036)	3.4%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	England generic medicine distribution corridors

United Kingdom Celecoxib Market Outlook

• United Kingdom celecoxib API sales are backed by generic capsule listings and regulated finished-dose supply. Marketing authorization holders need API vendors that can support release records and supply continuity.
• Buyer preference is expected to move toward vendors offering stronger quality documents. NHS-linked pricing discipline keeps margins measured.

Key Growth Drivers

• Capsule supply remains listed in reimbursed channels, indicated by NHSBSA's December 2025 tariff showing celecoxib 100 mg capsules in packs of 60 at 201 pence and 200 mg capsules in packs of 30 at 197 pence.

• Clinical dosing visibility supports finished-dose planning, recorded by NICE BNF guidance for adult osteoarthritis at 200 mg daily in 1 to 2 divided doses before escalation to 200 mg twice daily if needed.
• UK product holders need dependable API documents to avoid release disruption.
• Distributor screening helps smaller formulation buyers compare suppliers before direct qualification.

Key Restraints

• NHS tariff pressure can limit finished-dose price recovery and API margin improvement.
• Formulary controls can restrict routine use in selected hospital systems, illustrated by Imperial NHS formulary material from May 2026 listing 2 celecoxib capsule strengths as restricted.
• Supplier changes may face slower adoption if batch histories and file access are incomplete.

What makes United Kingdom unique

United Kingdom is distinct through tariff-based pricing visibility and hospital formulary discipline.

Key Companies

• Accord-UK
• Teva UK
• Zentiva Pharma UK
• Viatris UK
• Dr. Reddy's Laboratories UK
• Sandoz UK

Sales & Marketing Channels

• Direct supply through marketing authorization holders
• Wholesaler-linked generic medicine channels
• Distributor support for early supplier screening
• Documentation-led account retention
• Audit-based supplier approval
• Online API discovery for smaller buyers

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	99.5% or Higher · 98.0% to 99.5% · Below 98%
By Application	Osteoarthritis · Rheumatoid Arthritis · Acute Pain
By Sales Channel	Direct · Distributors · Online API Marketplaces
By Buyer Type	Finished-Dosage Manufacturers · API Distributors · Contract Manufacturers · Regulatory-File Developers · Generic Product Sponsors
Key Sub-Regions Covered, Formulation Corridors	England · Midlands · North West England · South East England · Wales · Scotland

Frequently Asked Questions

How fast is United Kingdom Celecoxib market growing?

United Kingdom demand is projected to rise at 3.4% CAGR from 2026 to 2036, supported by reimbursed capsule listings and medicine-supply continuity.

Who leads United Kingdom Celecoxib market?

Accord-UK, Teva UK, Zentiva Pharma UK, Viatris UK, Dr. Reddy's Laboratories UK, and Sandoz UK lead United Kingdom Celecoxib market through generic medicine supply and pharmacy access.

What is driving adoption in United Kingdom Celecoxib market?

Tariff-listed capsule demand and marketing authorization maintenance are supporting API sourcing from documented suppliers in United Kingdom.

What is driving Celecoxib Market growth in France?

A 3.1% CAGR through 2036 reflects generic directory activity and EU product maintenance.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 0.73 million
Market Size in 2026 (Value)	USD 0.75 million
Market Forecast in 2036 (Value)	USD 1.02 million
CAGR (2026 to 2036)	3.1%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	Ile-de-France and Auvergne-Rhone-Alpes pharmaceutical corridors

France Celecoxib Market Outlook

• France celecoxib API demand is supported by generic-directory activity and regulated product maintenance. API suppliers need EU-ready files and predictable batch behavior to serve product holders.
• Generic substitution structures keep finished-dose demand active. Reimbursement pressure remains, although documented suppliers can retain access through file stability and audit support.

Key Growth Drivers

• Generic directory activity supports product continuity, evidenced by ANSM's February 2025 decision adding 2 CELECOXIB TEVA SANTE capsule entries.
• Product identification remains strict for French generic listings, as ANSM's March 2025 directory states each specialty record includes 4 core fields, name, dosage, pharmaceutical form, and marketing authorization holder.
• French generic product holders need reliable API files for directory-linked maintenance.
• EU-qualified suppliers gain buyer preference through impurity records and dossier support.

Key Restraints

• Reimbursement discipline can limit finished-dose pricing and API margin improvement.
• Directory maintenance increases review work for product holders, as ANSM's March 2025 generic directory was published as a 622-page reference document.
• Product holders may delay supplier changes if quality records require extra review.

What makes France unique

France is set apart by structured product-field disclosure and reimbursement-linked substitution controls.

Key Companies

• Biogaran
• Teva Santé
• Viatris Santé
• Zentiva France
• Arrow Génériques
• EG Labo

Sales & Marketing Channels

• Direct supply to EU product holders
• Distributor access for supplier screening
• Documentation-led selling through regulated accounts
• EU DMF and CEP support channels
• Quality-audit driven account development
• Online API marketplaces for discovery

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	99.5% or Higher · 98.0% to 99.5% · Below 98%
By Application	Osteoarthritis · Rheumatoid Arthritis · Acute Pain
By Sales Channel	Direct · Distributors · Online API Marketplaces
By Buyer Type	Finished-Dosage Manufacturers · API Distributors · Contract Manufacturers · Regulatory-File Developers · Generic Product Sponsors
Key Sub-Regions Covered, Formulation Corridors	Ile-de-France · Auvergne-Rhone-Alpes · Hauts-de-France · Normandy · Grand Est · Provence-Alpes-Cote d'Azur

Frequently Asked Questions

How fast is France Celecoxib market growing?

France demand is projected to rise at 3.1% CAGR from 2026 to 2036, supported by generic-directory activity and EU product maintenance.

Who leads France Celecoxib market?

Biogaran, Teva Santé, Viatris Santé, Zentiva France, Arrow Génériques, and EG Labo lead France Celecoxib market through generic directory access and retail pharmacy reach.

What is driving adoption in France Celecoxib market?

Generic group maintenance and reimbursement-linked medicine access are moving France buyers toward qualified API supply.

What is the Celecoxib Market forecast for Germany?

A 2.9% CAGR through 2036 reflects regulated continuity and dossier-linked supplier discipline.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 0.86 million
Market Size in 2026 (Value)	USD 0.89 million
Market Forecast in 2036 (Value)	USD 1.18 million
CAGR (2026 to 2036)	2.9%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	Rhine-Ruhr and Bavaria pharmaceutical corridors

Germany Celecoxib Market Outlook

• Germany celecoxib API demand is supported by EU product maintenance and disciplined generic sourcing. Dossier stability matters as supplier changes can affect product lifecycle work.
• Buyers are expected to prefer vendors with strong EU documentation. Sickness-fund contracting limits pricing room, yet reliable API files can protect repeat accounts.

Key Growth Drivers

• EU product-file activity keeps celecoxib products under maintenance, supported by EMA's September 2024 nationally authorised product list spanning 29 pages.
• Safety-review processes increase documentation needs, reflected by EMA PRAC meeting minutes published in March 2025 across 116 pages.
• German buyers weigh supplier-change risk carefully during dossier updates.
• Qualified API suppliers benefit from stability-history review and European document readiness.

Key Restraints

• Sickness-fund contracting can restrict finished-dose price improvement and limit API margin room.
• National safety and product-information review adds caution to supplier switches, supported by BfArM's 2025 therapy compass listing celecoxib adult dosing at 1 to 2 administrations of 100 mg to 200 mg per day.
• Mid-sized formulation buyers can delay supplier change if validation resources are limited.

What makes Germany unique

Germany is differentiated by BfArM product-information access and sickness-fund contracting pressure.

Key Companies

• Ratiopharm
• Hexal
• 1A Pharma
• Aristo Pharma
• Viatris Germany
• Zentiva Germany

Sales & Marketing Channels

• Direct API supply to regulated product holders
• European distributor screening
• EU DMF and CEP-supported account development
• Technical documentation support through qualified accounts
• Audit-driven customer qualification
• Online API discovery for early comparison

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	99.5% or Higher · 98.0% to 99.5% · Below 98%
By Application	Osteoarthritis · Rheumatoid Arthritis · Acute Pain
By Sales Channel	Direct · Distributors · Online API Marketplaces
By Buyer Type	Finished-Dosage Manufacturers · API Distributors · Contract Manufacturers · Regulatory-File Developers · Generic Product Sponsors
Key Sub-Regions Covered, Formulation Corridors	Rhine-Ruhr · Bavaria · Baden-Wurttemberg · Hesse · Hamburg · Berlin-Brandenburg

Frequently Asked Questions

How fast is Germany Celecoxib market growing?

Germany demand is projected to rise at 2.9% CAGR from 2026 to 2036, supported by EU product maintenance and dossier-linked supplier discipline.

Who leads Germany Celecoxib market?

Ratiopharm, Hexal, 1A Pharma, Aristo Pharma, Viatris Germany, and Zentiva Germany lead Germany Celecoxib market through generic pharmacy supply and regulated product files.

What is driving adoption in Germany Celecoxib market?

Dossier continuity and pharmacy-driven generic supply are supporting demand for audit-ready celecoxib API in Germany.

What is the Celecoxib market forecast for Japan?

A 2.7% CAGR through 2036 reflects pharmacopoeial activity and careful supplier review.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 0.90 million
Market Size in 2026 (Value)	USD 0.92 million
Market Forecast in 2036 (Value)	USD 1.20 million
CAGR (2026 to 2036)	2.7%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	Kanto and Kansai pharmaceutical corridors

Japan Celecoxib Market Outlook

• Japan celecoxib API demand is supported by standards activity and conservative supplier qualification. Product holders give weight to analytical methods and documented batch consistency.
• Supplier changes are expected to remain cautious. Japan-facing documentation and stable crystal-form control improve supplier acceptance across finished-dose accounts.

Key Growth Drivers

• Pharmacopoeial review supports method alignment, demonstrated by PMDA's September 2024 public-comment page listing Celecoxib Tablets at 101 KB.
• Product-quality disclosure remains active, recorded by PMDA's December 2025 column document listing Celecoxib Tablets under 2 tests, uniformity of dosage unit and assay.
• Japanese formulation buyers value established supplier history and analytical method support.
• API vendors with Japan-facing documentation can strengthen access during product-file updates.

Key Restraints

• Conservative qualification processes can slow supplier approval in regulated formulation accounts.
• Safety-review discipline adds product-maintenance work, shown by PMDA's October 2024 precautions revision identifying celecoxib within 1 antipyretic and anti-inflammatory agent class.
• Smaller buyers may avoid supplier replacement if local documentation support is weak.

What makes Japan unique

Japan differs through pharmacopoeial rigor and high expectations for analytical support.

Key Companies

• Sawai Pharmaceutical
• Towa Pharmaceutical
• Nichi-Iko Pharmaceutical
• Meiji Seika Pharma
• Viatris Japan
• Pfizer Japan

Sales & Marketing Channels

• Direct regulated buyer qualification
• Japan-facing distributor relationships
• Technical documentation support for product maintenance
• Quality-audit driven supplier review
• API marketplace screening for early comparisons
• Customer-specific analytical support

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	99.5% or Higher · 98.0% to 99.5% · Below 98%
By Application	Osteoarthritis · Rheumatoid Arthritis · Acute Pain
By Sales Channel	Direct · Distributors · Online API Marketplaces
By Buyer Type	Finished-Dosage Manufacturers · API Distributors · Contract Manufacturers · Regulatory-File Developers · Generic Product Sponsors
Key Sub-Regions Covered, Formulation Corridors	Kanto · Kansai · Chubu · Kyushu · Tohoku · Setouchi industrial belt

Frequently Asked Questions

How fast is Japan Celecoxib market growing?

Japan demand is projected to rise at 2.7% CAGR from 2026 to 2036, supported by pharmacopoeial activity and careful supplier review.

Who leads Japan Celecoxib market?

Sawai Pharmaceutical, Towa Pharmaceutical, Nichi-Iko Pharmaceutical, Meiji Seika Pharma, Viatris Japan, and Pfizer Japan lead Japan Celecoxib market through generic production and local commercial supply.

What is driving adoption in Japan Celecoxib market?

Pharmacopoeial review and conservative supplier qualification are supporting demand for documented crystalline API in Japan.

What is the Celecoxib Market outlook in South Korea?

A 2.4% CAGR through 2036 reflects regulated generic access and import-document expectations.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 0.37 million
Market Size in 2026 (Value)	USD 0.38 million
Market Forecast in 2036 (Value)	USD 0.48 million
CAGR (2026 to 2036)	2.4%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	Seoul-Incheon and Gyeonggi pharmaceutical corridors

South Korea Celecoxib Market Outlook

• South Korea celecoxib API demand is supported by regulated generic formulation and import documentation. Finished-dose firms usually purchase through qualified API relationships.
• Suppliers are expected to compete through batch traceability and MFDS-facing support. Export-ready documentation improves buyer confidence during source approval.

Key Growth Drivers

• Regulated approval activity supports file-ready API suppliers, evidenced by MFDS publishing the 2024 Drug Approval Report as item 59 on its English products page in 2025.
• Documentation needs remain central to Korean supply access, reinforced by MFDS generic requirements covering 3 document groups, bioequivalence study along with GMP documents, and CMC data.
• Korean formulation buyers give weight to traceable batch records and quality response speed.
• Finished-dose manufacturers prefer suppliers able to support local review without repeated file corrections.

Key Restraints

• Reimbursement pressure can limit API price improvement for mature pain products.
• Post-market safety screening can slow source approval for mature pain products, as a 2024 Journal of Korean Medical Science analysis of KIDS-KAERS data began with 2,038,309 adverse drug event reports and retained 793,498 adult reports after filtering.
• Smaller buyers may depend on distributors if direct supplier audits require added internal resources.

What makes South Korea unique

South Korea is distinguished by MFDS-facing documentation and quality-led import qualification.

Key Companies

• Chong Kun Dang
• Hanmi Pharm
• Daewoong Pharmaceutical
• Celltrion Pharm
• Samjin Pharmaceutical
• Viatris Korea

Sales & Marketing Channels

• Direct API qualification through finished-dose buyers
• Distributor support for early supplier screening
• Regulatory documentation support for import-linked sourcing
• Quality-audit driven account development
• Technical dossiers through customer review teams
• Online API marketplace discovery

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	99.5% or Higher · 98.0% to 99.5% · Below 98%
By Application	Osteoarthritis · Rheumatoid Arthritis · Acute Pain
By Sales Channel	Direct · Distributors · Online API Marketplaces
By Buyer Type	Finished-Dosage Manufacturers · API Distributors · Contract Manufacturers · Regulatory-File Developers · Generic Product Sponsors
Key Sub-Regions Covered, Formulation Corridors	Seoul · Incheon · Gyeonggi · Chungcheong · Busan · Daegu

Frequently Asked Questions

How fast is South Korea Celecoxib market growing?

South Korea demand is projected to rise at 2.4% CAGR from 2026 to 2036, supported by regulated generic demand and import-document expectations.

Who leads South Korea Celecoxib market?

Chong Kun Dang, Hanmi Pharm, Daewoong Pharmaceutical, Celltrion Pharm, Samjin Pharmaceutical, and Viatris Korea lead South Korea Celecoxib market through domestic generics and regulated supply access.

What is driving adoption in South Korea Celecoxib market?

MFDS-facing documentation and finished-dose qualification are moving South Korea buyers toward traceable API suppliers.

What is the Celecoxib Market outlook in China?

A 1.8% CAGR through 2036 reflects domestic generic capacity and approval activity.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 1.13 million
Market Size in 2026 (Value)	USD 1.15 million
Market Forecast in 2036 (Value)	USD 1.37 million
CAGR (2026 to 2036)	1.8%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	Yangtze River Delta and coastal pharmaceutical corridors

China Celecoxib Market Outlook

• China celecoxib API demand is supported by domestic generic manufacturing and formulation scale. Local product approvals keep finished-dose activity active across price-sensitive channels.
• Suppliers are expected to compete through cost discipline and registration support. Buyers will favor vendors able to combine price competitiveness with stable quality files.

Key Growth Drivers

• Domestic formulation scale benefits from review modernization, as NMPA's October 2025 announcement created a 30-day pathway for eligible innovative drug clinical trial applications.
• API-related supervision is becoming more structured, with NMPA's June 2025 announcement covering 3 registered supply groups, APIs together with excipients, and pharmaceutical packaging materials.
• Local formulation scale supports demand for cost-efficient API suppliers.
• Registration-support capability improves supplier access to finished-dose accounts.

Key Restraints

• Provincial price pressure can limit finished-dose pull and reduce API value.
• Quality oversight can raise audit burden, as NMPA's June 2025 supervision announcement directs provincial regulators to inspect registration-platform entries marked A.
• Competition among finished-dose holders increases pricing pressure for commodity generic suppliers.

What makes China unique

China stands apart through centralized drug review reform and price-sensitive formulation channels.

Key Companies

• Jiangsu Hengrui Medicine
• Qilu Pharmaceutical
• CSPC Pharmaceutical
• Zhejiang Medicine
• Simcere Pharmaceutical
• Shenzhen HwaGen Pharmaceutical

Sales & Marketing Channels

• Domestic formulation supplier relationships
• Distributor-led API discovery
• Direct technical qualification for regulated accounts
• Registration-support based selling
• Online API marketplaces
• Quality-audit based customer conversion

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	99.5% or Higher · 98.0% to 99.5% · Below 98%
By Application	Osteoarthritis · Rheumatoid Arthritis · Acute Pain
By Sales Channel	Direct · Distributors · Online API Marketplaces
By Buyer Type	Finished-Dosage Manufacturers · API Distributors · Contract Manufacturers · Regulatory-File Developers · Generic Product Sponsors
Key Sub-Regions Covered, Formulation Corridors	Yangtze River Delta · Jiangsu · Zhejiang · Shandong · Guangdong · Hebei

Frequently Asked Questions

How fast is China Celecoxib market growing?

China demand is projected to rise at 1.8% CAGR from 2026 to 2036, supported by domestic generic capacity and approval activity.

Who leads China Celecoxib market?

Jiangsu Hengrui Medicine, Qilu Pharmaceutical, CSPC Pharmaceutical, Zhejiang Medicine, Simcere Pharmaceutical, and Shenzhen HwaGen Pharmaceutical lead China Celecoxib market through domestic manufacturing and registration support.

What is driving adoption in China Celecoxib market?

Domestic capsule approvals and formulation scale are moving China buyers toward cost-efficient qualified API suppliers.

How fast is the Celecoxib market growing in India?

A 1.6% CAGR through 2036 reflects API manufacturing depth and export documentation.

Country Market Snapshot Table

Parameter	Value
Market Size in 2025 (Value)	USD 0.73 million
Market Size in 2026 (Value)	USD 0.74 million
Market Forecast in 2036 (Value)	USD 0.87 million
CAGR (2026 to 2036)	1.6%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD million)
Leading Sub-Region	Maharashtra, Gujarat, Telangana, and Andhra Pradesh API corridors

India Celecoxib Market Outlook

• India celecoxib API sales are supported by manufacturing depth and regulated export preparation. Finished-dose and API buyers favor suppliers able to provide compendial alignment and quick document response.
• Local suppliers benefit from cost position and export familiarity. Competitive pressure remains active. Supplier breadth helps India serve regulated and semi-regulated accounts.

Key Growth Drivers

• Compendial activity supports regulated product work, reflected by IPC's June 2024 draft for Celecoxib Capsules listing 100 mg and 200 mg usual strengths.
• Export-linked supplier files support EU-directed API trade, shown by CDSCO's May 2026 written confirmation for Aurore Life Sciences covering Celecoxib USP/Ph.Eur across 1 manufacturing and packing site.
• Domestic API suppliers gain access as buyers prefer fast document response and local technical follow-up.
• Finished-dose firms keep celecoxib in sourcing plans as pain and arthritis products require stable input quality.

Key Restraints

• Price competition limits supplier margins across mature generic API accounts.
• Documentation upkeep adds cost for suppliers maintaining several customer files.
• Export qualification can require repeated file maintenance, reflected by CDSCO's February 2026 written confirmation for Aarti Drugs remaining valid for 3 years.

What makes India unique

India is marked by IPC monograph activity and export-oriented documentation capacity.

Key Companies

• Hikal
• Aurore Life Sciences
• Aarti Drugs
• Hetero Labs
• Glochem Industries
• Saurav Chemicals

Sales & Marketing Channels

• Direct API sales to finished-dosage manufacturers
• Distributor support for smaller formulation buyers
• Export-linked filing support through regulated customer relationships
• Quality-audit driven customer qualification
• Online API marketplace discovery
• Technical documentation support for overseas buyers

Country Segment Breakdown Table

Segment	Sub-Segments
By Form	Powder · Crystalline
By Purity Grade	99.5% or Higher · 98.0% to 99.5% · Below 98%
By Application	Osteoarthritis · Rheumatoid Arthritis · Acute Pain
By Sales Channel	Direct · Distributors · Online API Marketplaces
By Buyer Type	Finished-Dosage Manufacturers · API Distributors · Contract Manufacturers · Regulatory-File Developers · Generic Product Sponsors
Key Sub-Regions Covered, API Corridors	Maharashtra · Gujarat · Telangana · Andhra Pradesh · Karnataka · Himachal Pradesh

Frequently Asked Questions

How fast is India Celecoxib market growing?

India demand is projected to rise at 1.6% CAGR from 2026 to 2036, supported by API manufacturing depth and export documentation.

Who leads India Celecoxib market?

Hikal, Aurore Life Sciences, Aarti Drugs, Hetero Labs, Glochem Industries, and Saurav Chemicals lead India Celecoxib market through local API manufacturing and export-ready documentation.

What is driving adoption in India Celecoxib market?

Compendial updates and export-linked documentation are supporting demand for qualified celecoxib API suppliers in India.

Who are the leading companies in the Celecoxib Market?

Hikal, Aurore Life Sciences, Aarti Drugs, Axplora/Farmabios, and Hetero Labs.

• Established API companies hold an advantage due to regulated manufacturing depth and audit-ready documents.
• European and India-based suppliers gain stronger acceptance by linking crystal-form control with DMF and CEP support.
• Regional API suppliers win country accounts by offering faster document response and cost-efficient manufacturing.
• Filing-ready suppliers improve renewal chances based on particle-size data and impurity control records.

API manufacturers compete by combining solid-form control and regulatory documentation. Hikal has a strong position through public API portfolio visibility and regulated-market contact coverage. Aurore Life Sciences competes through filing-status preparation and export-linked support. Aarti Drugs holds buyer attention through active API manufacturing and written confirmation evidence.

Manufacturing quality and documentation depth have become stronger separators as complex generics buyers move beyond price checks. Axplora/Farmabios competes through Form III celecoxib, fine and micronized grades, and EU-linked filings. Hetero Labs, Glochem Industries, Saurav Chemicals, and Shenzhen HwaGen Pharmaceutical strengthen competition through regional manufacturing and formulation-buyer access. Buyers compare suppliers through crystallinity and regulatory response time.

Smaller and regional suppliers can win through local manufacturing access and faster document support. India and China create opportunities for suppliers with cost-efficient production and export records. United States and Europe create stronger demand for DMF or CEP documentation. Companies that prove stable API quality under regulated review should gain durable supply contracts.

How do top Celecoxib companies compare?

Hikal and Aurore Life Sciences score on regulated API access while Axplora/Farmabios leads through Form III documentation depth.

Company	Relevance to Market Title	Form Control Strength	Regulatory Documentation Depth	Channel Reach	Geographic Footprint
Hikal	Very High	Strong	Strong	Strong	India, United States, and Japan
Aurore Life Sciences	Very High	High	Strong	Strong	India and regulated export markets
Aarti Drugs	High	Strong	Strong	Moderate	India and export markets
Axplora/Farmabios	Very High	Strong	Very Strong	Strong	Europe and North America
Hetero Labs	High	Moderate	Strong	Strong	India and global generics
Glochem Industries	Moderate	Moderate	Moderate	Moderate	India
Saurav Chemicals	Moderate	Moderate	Moderate	Moderate	India
Shenzhen HwaGen Pharmaceutical	Moderate	Moderate	Moderate	Moderate	China and export markets

Source: Future Market Insights competitive analysis, 2026.

Who are the key players in the Celecoxib Market?

Hikal, Aurore Life Sciences and Aarti Drugs are listed with Axplora/Farmabios and Hetero Labs among other suppliers.

Key global companies leading the Celecoxib Market include:

• Hikal
• Aurore Life Sciences
• Aarti Drugs
• Axplora/Farmabios
• Hetero Labs
• Glochem Industries
• Saurav Chemicals
• Shenzhen HwaGen Pharmaceutical

Key Developments in Celecoxib Market

• In May 2026, CDSCO issued written confirmation documentation for Aurore Life Sciences covering Celecoxib USP/Ph.Eur for manufacturing and packing.
• In February 2026, CDSCO issued written confirmation documentation for Aarti Drugs covering Celecoxib BP/Ph.Eur/USP for manufacturing and packing.
• In April 2024, Axplora listed Celecoxib Form III in fine and micronized grades with CEP, EU DMF, United States DMF, and Canada DMF support.

Key Players in the Celecoxib Market

India-Based API Manufacturers

• Hikal
• Aurore Life Sciences
• Aarti Drugs
• Hetero Labs

European and Global DMF Suppliers

• Axplora/Farmabios
• Aurore Life Sciences
• Hikal

Regional API Suppliers

• Glochem Industries
• Saurav Chemicals
• Shenzhen HwaGen Pharmaceutical

Documentation and Filing-Focused Suppliers

• Hikal
• Aurore Life Sciences
• Aarti Drugs
• Axplora/Farmabios

Celecoxib Market - Scope & Definition

Attribute	Detail
Market Definition	Commercially traded celecoxib active pharmaceutical ingredient supplied as powder or crystalline material for finished medicines used in osteoarthritis, rheumatoid arthritis, and acute pain
Functions Covered	Anti-inflammatory API supply, capsule formulation input, impurity-controlled material supply, particle-size control, and regulatory-file support
Applications Covered	Osteoarthritis, Rheumatoid Arthritis, and Acute Pain finished-dose formulations
End-Use Industries	Finished-dosage manufacturers, contract manufacturers, API distributors, regulatory-file developers, and generic product sponsors
Grades Covered	99.5% or Higher, 98.0% to 99.5%, Below 98%, crystalline grades, powder grades, and Form III material
Inclusions	Celecoxib API sold across form, purity grade, application, sales channel, buyer type, region, and country-level regulated supply use
Exclusions	Finished capsule revenue, retail medicine sales, branded drug revenue, hospital prescribing services, other NSAID APIs, etoricoxib, parecoxib, valdecoxib, excipients, and non-celecoxib analgesic formulation revenue

Celecoxib Market - Research Methodology

Method	Description
Primary Research	FMI analyst interviews with API sourcing teams, finished-dosage manufacturers, pharmaceutical distributors, contract manufacturers, and regulatory-file specialists
Desk Research	Review of official drug labels, product-specific guidance, pharmacopoeial drafts, regulatory product lists, company API portfolios, written confirmations, and generic medicine records
Market Sizing & Forecasting	Bottom-up API value approach using capsule demand, purity-grade mix, form share, direct-channel adoption, buyer qualification patterns, and country-level generic product exposure
Data Validation	Cross-verification using regulator records, company portfolios, drug tariff evidence, compendial updates, country product records, and supplier filing indicators

Celecoxib Market - Report Scope

Parameter	Details
Forecast period	2026 to 2036
Historical period	2021 to 2025
Quantitative unit	Revenue in USD million
By form	Powder, Crystalline
By purity grade	99.5% or Higher, 98.0% to 99.5%, Below 98%
By application	Osteoarthritis, Rheumatoid Arthritis, Acute Pain
By sales channel	Direct, Distributors, Online API Marketplaces
By buyer type	Finished-Dosage Manufacturers, API Distributors, Contract Manufacturers, Regulatory-File Developers, Generic Product Sponsors
Regions covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries covered	United States, United Kingdom, France, Germany, Japan, South Korea, China, India
Key companies profiled	Hikal, Aurore Life Sciences, Aarti Drugs, Axplora/Farmabios, Hetero Labs, Glochem Industries, Saurav Chemicals, Shenzhen HwaGen Pharmaceutical
Approach	Bottom-up API value approach using finished-dose demand, purity-grade mix, regulatory filing depth, supplier qualification behavior, small molecule API sourcing, and country-level generic medicine exposure

Source: Future Market Insights competitive analysis, 2026.

Celecoxib Market Breakdown by Form, Purity Grade, Application, Sales Channel, Buyer Type, and Region

Celecoxib Market Segmented by Form

• Powder
• Crystalline

Celecoxib Market Segmented by Purity Grade

• 99.5% or Higher
• 98.0% to 99.5%
• Below 98%

Celecoxib Market Segmented by Application

• Osteoarthritis
• Rheumatoid Arthritis
• Acute Pain

Celecoxib Market Segmented by Sales Channel

• Direct
• Distributors
• Online API Marketplaces

Celecoxib Market Segmented by Buyer Type

• Finished-Dosage Manufacturers
• API Distributors
• Contract Manufacturers
• Regulatory-File Developers
• Generic Product Sponsors

Celecoxib Market by Region

• North America
• Latin America
• Europe
• East Asia
• South Asia and Pacific
• Middle East and Africa

Research Sources and Bibliography

• Axplora. (2024, April). Product portfolio: Generic API products.
• Central Drugs Standard Control Organisation. (2026, February). Written confirmation for Aarti Drugs active substances imported into the European Union.
• Central Drugs Standard Control Organisation. (2026, May). Written confirmation for Aurore Life Sciences active substances imported into the European Union.
• Centers for Disease Control and Prevention. (2024, November). Chronic pain and high-impact chronic pain in USA adults, 2023.
• DailyMed. (2025, September). Celecoxib capsule prescribing information.
• European Medicines Agency. (2024, September). Celecoxib: List of nationally authorised medicinal products.
• European Medicines Agency. (2025, March). Minutes of PRAC meeting on 2-5 September 2024.
• Federal Institute for Drugs and Medical Devices. (2025). Long COVID therapy compass.
• French National Agency for Medicines and Health Products Safety. (2025, February). Decision modifying the generic medicines directory.
• French National Agency for Medicines and Health Products Safety. (2025, March). Generic medicines directory.
• Indian Pharmacopoeia Commission. (2024, June). Draft proposal for Celecoxib Capsules.
• Indian Pharmacopoeia Commission. (2025). Annual report 2024-25.
• Ministry of Food and Drug Safety. (2025, July). 2024 Drug Approval Report.
• Kim, G. J., Lee, J. S., Jang, S., Lee, S., Jeon, S., Lee, S., Kim, J. H., & Lee, K. H. (2024). Polypharmacy and elevated risk of severe adverse events in older adults based on the Korea Institute of Drug Safety and Risk Management-Korea Adverse Event Reporting System database. Journal of Korean Medical Science, 39, e205.
• Ministry of Food and Drug Safety. (2025). Generic drug approval process.
• National Health Service Business Services Authority. (2025, December). Drug Tariff Part VIIIA.
• National Institute for Health and Care Excellence. (2025). Celecoxib: British National Formulary entry.
• National Medical Products Administration. (2025, June). Announcement on issuing pharmaceutical excipient and packaging material supervision requirements.
• National Medical Products Administration. (2025, October). Announcement on optimizing review and approval process for clinical trials of innovative drugs.
• Pharmaceuticals and Medical Devices Agency. (2024, September). JP drafts for public comments: Celecoxib Tablets.
• Pharmaceuticals and Medical Devices Agency. (2024, October). Revision of precautions: Celecoxib.
• Pharmaceuticals and Medical Devices Agency. (2025, December). Information about columns for Japanese Pharmacopoeia draft monographs.
• USA Food and Drug Administration. (2024, November). Celebrex supplement approval letter.
• USA Food and Drug Administration. (2025, May). Draft guidance on Celecoxib.
• USA Food and Drug Administration. (2026, May). Office of Generic Drugs.
• USA Food and Drug Administration. (2026, April). List of Drug Master Files.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• Market size estimates for 2026 and forecasts through 2036 for the Celecoxib Market.
• Insights across regional and country-level celecoxib API supply markets.
• Analysis of demand drivers and purchasing behavior.
• Evaluation of form, purity grade, application, sales channel, and buyer type.
• Assessment of regulatory guidance and product-file maintenance.
• Identification of opportunities across crystalline API and high-purity supply.
• Evaluation of direct sales models and technical qualification channels.
• Country-level analysis covering United States, United Kingdom, France, Germany, Japan, South Korea, China, and India.
• Assessment of competition, including leading API manufacturers and regulated filing suppliers.
• Analysis of batch-release decision drivers and renewal criteria.
• Regional outlooks across North America, Europe, East Asia, South Asia and Pacific, Latin America, and Middle East and Africa.
• Delivery of market data, forecasts, and supporting analysis in report-ready format.